SGLT2 抑制剂达格列净在心血管疾病中的应用进展

糖尿病与心血管疾病关系密切,治疗糖尿病的药物对心血管预后也有不同的影响。SGLT2抑制剂达格列净是治疗2型糖尿病的新药,目前有较多研究显示其能明显降低心血管风险事件的发生,特别是能明显改善糖尿病伴心力衰竭患者的临床症状、减少住院率和死亡率,还能改善心肌缺血、抑制心肌重塑、降低血压、减轻体重,对血脂、尿酸等均有不同程度的影响。达格列净对心血管系统作用是多方面的,获益也是多方面的,有望成为治疗糖尿病伴心血管疾病的理想药物。

Progress in application of SGLT2 inhibitor Dapagliflozin in cardiovascular diseases

Diabetes is closely related to cardiovascular disease,and the drugs for treating diabetes also have different effects on cardiovascular prognosis.SGLT2 inhibitor dapagliflozin is a new drug for the treatment of type 2 diabetes mellitus.There are many studies showing that it can significantly reduce the occurrence of cardiovascular risk events.In particular,it can significantly improve the clinical symptoms,reduce hospitalization rate and mortality of patients with diabetes and heart failure.Dapagliflozin can not only decrease myocardial ischemia and prevent myocardial remodeling but also lower blood pressure or reduce body weight.It has varying degrees influence on blood lipids and serum uric acid.Dapagliflozin has many effects and benefits on cardiovascular system.It is expected to be an ideal drug for the treatment of diabetes mellitus with cardiovascular disease.